Morgan Stanley Cardiol Therapeutics Inc. Transaction History
Morgan Stanley
- $1.36 Trillion
- Q1 2025
A detailed history of Morgan Stanley transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 59,613 shares of CRDL stock, worth $83,458. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,613
Previous 204,543
70.86%
Holding current value
$83,458
Previous $263,000
78.33%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CRDL
# of Institutions
44Shares Held
7.82MCall Options Held
25.9KPut Options Held
1.7K-
Tejara Capital LTD London, X03.19MShares$4.47 Million1.2% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD982KShares$1.38 Million0.19% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9783KShares$1.1 Million0.35% of portfolio
-
Ubs Group Ag498KShares$696,9990.0% of portfolio
-
Pvg Asset Management Corp Golden, CO437KShares$612,3061.99% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $86.7M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...